RATIONALE: Fungal spores with allergenic potential are a predominant biological component in the atmosphere of Puerto Rico. Spores of basidiomycete fungi, such as Ganoderma spp, often outnumber the atmospheric concentration of mitosporic fungi and pollen from trees and grass. Nevertheless, extracts from basidiomycetes are not currently available for serological testing and knowledge of the relationship of reactivity with commercial extracts is limited. METHODS: Spearman correlation matrices were generated, on an archived dataset, to identify relationships between reactivity to G. applanatum spore's cytoplasmic extracts tested in ELISA (crude) and Western blot (19, 24, 33, 45, 56, 75, and 81 kDa) with reactivity to indoor, pests, farm animals, and pollen allergens commercial extracts. Also, principal component analysis was employed to identify clusters of variables explaining inter-subjects variabilities in reactivities. RESULTS: Only the reactivity to dog danger was highly correlated with the crude extract (r 50.48, p < 0.001), but the 45 and 75 kDa polypeptides were correlated with reactivities to mitosporic fungi (Alternaria, Aspergillus, Fusarium, Cladosporium), Mucor, pests (American cockroach, mouse, rat), and farm animal danders (chicken, horse) (r 5 .30 to 57, p 5 0.04 to < 0.001). G. applanatums polypeptides (except the 19 kDa) clustered together in explaining 21% of the variability among the subjects' reactivities. CONCLUSIONS: These results suggests that reactivity to mitosporic fungi, indoor allergens, and allergens from farm animals pose a respiratory health risk from exposures to G. applanatum fungal spores. Our findings also further support the relevance of G. applamatum as an important outdoor allergen among the Puerto Rico population. RATIONALE: Household endotoxin levels have been variably associated with asthma and atopy. We present a combined epidemiologic and mechanistic study of the relationship between endotoxin and food allergen sensitization. METHODS: Logistic regression models were built using data from the 2005-2006 National Health and Nutrition Examination Survey (NHANES, n56963), a large cohort representative of the US population, to test for associations between house dust endotoxin (log-transformed) and sensitization to specific foods (milk, egg, and peanut). To characterize inflammatory responses to endotoxin in individuals with vs. without food allergen sensitization, peripheral blood mononuclear cells (PBMCs) were collected from 21 children mono-allergic to milk, egg, or peanut and non-allergic controls. Following stimulation with endotoxin, cytokines were measured using the Luminex platform. RESULTS: Among NHANES subjects, the geometric mean endotoxin level was 15.5 EU/mg (SE 0.5). Prevalence of food allergen sensitization (sIgE > _0.35 kU<SUB>A</SUB>/L) varied by food: milk 5.7%, egg 4.0%, and peanut 7.9%. Household endotoxin level was associated with sensitization to milk (OR 1.7, 95%CI 1.2-2.1) and egg (OR 1.4, 95%CI 1.01-1.9), but not peanut (OR 0.98, 95%CI 0.8-1.2) in models adjusted for confounders. Interferon-gamma levels of endotoxin-stimulated PBMCs from individuals allergic to milk (mean 104.3 pg/ml) or egg (mean 44.4 pg/ ml) but not peanut (mean 240.8 pg/ml) were significantly lower on day 5 compared to controls (mean 536.1 pg/ml) (P-values 0.007, 0.018, and 0.058, respectively). CONCLUSIONS: Higher household endotoxin is associated with higher odds of milk and egg sensitization. Altered responsiveness to endotoxin is also observed in PBMCs from individuals with milk and egg allergy. RATIONALE: Data is sparse regarding omalizumab role's in the management of Chronic Urticaria (CU) in children. We aimed to evaluate management of CU and assess the effect of omalizumab in children. METHODS: Children with CU were prospectively recruited from the Montreal Children's Hospital from April 2013 to August 2018. Data were collected on demographics, co-morbidities, and management through a standardized questionnaire. Patients completed a weekly aggregated Urticaria Activity Score (UAS7). Tryptase, total IgE, C-reactive protein, and CD63 levels on basophiles were determined at study entry. Patients with suboptimal control of hives with up-dosing of antihistamines were treated with omalizumab. RESULTS: Over 5 years, 197 cases of CU were recruited, of which 50.8% were males and median age was 9.2 years. One-fifth of cases (20.8%) were diagnosed with physical urticaria and 12.7% were diagnosed with cholinergic urticaria. Autoimmune disease was reported in 7.1% of patients, mainly thyroiditis (2.5%). The most common antihistamines used were cetirizine (47.7%) and desloratadine (25.9%). Sixteen patients (8.1%) required treatment with omalizumab. Among these 16 patients, 56.3% were male with a median age of 11.6 years. Thirteen patients (81.3%) responded to our follow-up, of which 53.8% received 150 mg, 23.1% received 300 mg, and 15.4% received 450 mg of omalizumab. Following treatment, 69.2% reported complete resolution of hives, 23.1% reported fewer hives, and 7.7% found no effect. Of the 6 patients who stopped omalizumab, 4 reported recurrence of symptoms. CONCLUSIONS: Omalizumab can contribute to better management of CU in children but recurrence will occur in the majority of cases on cessation.
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